

10/529000

Application No.: Not Yet Assigned

Docket No.: 0020-5360PUS1

JC17 Rec'd PCT/PTO 24 MAR 2005

AMENDMENTS TO THE CLAIMS

1. (Original) An inducer of cytotoxic T cell (hereinafter, referred to as "CTL") comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.

2. (Original) A peptide which is a partial peptide of a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2 and is recognized by CTLs when bound to an HLA antigen.

3. (Original) The peptide of claim 2, wherein the HLA antigen is HLA-A24 or HLA-B55.

4. (Original) The peptide of claim 3, which comprises an amino acid sequence shown in any one of SEQ ID NO: 6 - 46.

5. (Original) The peptide of claim 3, which comprises an amino acid sequence wherein, in the sequence shown in any one of SEQ ID NO: 6-45, the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine or tryptophan, and/or the C terminal amino acid by phenylalanine, leucine, isoleucine, tryptophan or methionine.

6. (Currently amended) An epitope peptide comprising a peptide of ~~any one of claims 2 to 5~~ claim 2.

7. (Currently amended) An inducer of CTL comprising a peptide of ~~any one of claims 2 to 6~~ claim 2 as an active ingredient.

8. (Original) An inducer of CTL comprising a polynucleotide encoding a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.

9. (Original) The inducer of CTL of claim 8, wherein the polynucleotide is a polynucleotide comprising a base sequence shown in SEQ ID NO: 1, position 337-1878 of SEQ ID NO: 1 or SEQ ID NO: 3.

10. (Currently amended) A nucleic acid comprising a polynucleotide of ~~any one of claims 2 to 6~~ claim 2.

11. (Original) An inducer of CTL comprising the nucleic acid of claim 10.

12. (Currently amended) A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with any one of following (a) to (d) *in vitro*:

- (a) a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2;
- (b) a nucleic acid comprising a polynucleotide encoding the protein of (a);
- (c) a peptide set forth in ~~any one of any claims 2 to 6~~ claim 2; and
- (d) a nucleic acid comprising a polynucleotide encoding the peptide of (c).

13. (Original) An antigen-presenting cell obtainable according to the method of 12.

14. (Currently amended) A method for inducing a CTL comprising the step of bringing peripheral lymphocyte cells into contact with any one of following (a) to (d) *in vitro*:

- (a) a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2;
- (b) a nucleic acid comprising a polynucleotide encoding the protein of (a);
- (c) a peptide set forth in ~~any one of claims 2 to 6~~ claim 2; and

- (d) a nucleic acid comprising a polynucleotide encoding the peptide of (c).
- 15. The CTL inducible according to the method of 14.
- 16. (Currently amended) An antibody which specifically binds to the polypeptide of ~~any one of claims 2 to 5~~ claim 2.
- 17. (Original) A tumor marker comprising a polynucleotide and/or a complementary polynucleotide thereof, which polynucleotide comprises at least 15 contiguous nucleotides in the base sequence of a polynucleotide encoding a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.
- 18. (Original) The tumor marker of claim 17, which is a polynucleotide and/or a complementary polynucleotide thereof, said polynucleotide comprising at least 15 contiguous nucleotides in the base sequence of SEQ ID NO 1 or SEQ ID NO: 3.
- 19. (Original) A tumor marker comprising at least 8 contiguous amino acids in the amino acid sequence of a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.
- 20. (Original) The tumor marker of claim 19, which comprises at least 8 contiguous amino acids in the amino acid sequence shown in SEQ ID NO: 2.
- 21. (Original) A tumor marker comprising an antibody to a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO:2, or the antibody of claim 16.
- 22. (Original) The tumor marker of claim 21 comprising an antibody to a protein consisting of the amino acid sequence shown in SEQ ID NO:2.

23. (Currently amended) An HLA tetramer comprising a peptide of ~~any one of claims 2 to 5~~ claim 2 and an HLA antigen.
24. (Original) A tumor marker comprising the tetramer of claim 23.
25. (Currently amended) The tumor marker of ~~any one of claims 17-22 and 24~~ claim 17, wherein the tumor is sarcoma or renal cancer.
26. (Currently amended) A diagnostic agent for tumor comprising a tumor marker of ~~any one of claims 17-22 and 24-25~~ claim 17.